[Clinical phenotyping of severe Mycoplasma pneumoniae pneumonia in children]

H Wang1, W H Xu1, J R Liu1

  • 1Department Ⅱ of Respiratory Center, National Clinical Research Center for Respiratory Diseases, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China.

Insights

Severe pediatric Mycoplasma pneumoniae pneumonia (MPP) presents with varied imaging. A C-reactive protein (CRP) level of 67.5 mg/L can differentiate between lung consolidation-atelectasis-necrosis and lung consolidation-atelectasis subtypes in children.

Area of Science:

  • Pediatric Pulmonology
  • Infectious Diseases
  • Medical Imaging

Context:

  • Mycoplasma pneumoniae pneumonia (MPP) is a common cause of community-acquired pneumonia in children.
  • Severe cases of MPP can present with diverse clinical and radiological findings, necessitating accurate diagnosis and tailored treatment strategies.
  • Distinguishing between different subtypes of severe MPP is crucial for effective management and predicting patient outcomes.

Purpose:

  • To investigate and categorize pediatric patients with severe MPP based on clinical and chest imaging features.
  • To identify distinct subtypes within severe MPP, specifically focusing on lobar consolidation.
  • To evaluate the utility of C-reactive protein (CRP) as an early indicator for differentiating these subtypes.

Summary:

  • A retrospective study of 505 pediatric MPP patients identified 233 severe cases, categorized by imaging findings (lobar consolidation or diffuse bronchiolitis).
  • Severe lobar consolidation cases were further classified into 'lung consolidation-atelectasis-necrosis' (88 patients) and 'lung consolidation-atelectasis' (118 patients) subtypes.
  • The 'lung consolidation-atelectasis-necrosis' subtype showed higher CRP levels, more dyspnea, and greater pleural effusion. A CRP level of 67.5 mg/L on days 6-10 accurately distinguished between the two subtypes (AUC=0.97).

Impact:

  • This study provides a detailed characterization of severe pediatric MPP subtypes, aiding in a more precise diagnosis.
  • The identification of whole blood CRP as an early discriminating marker can guide individualized treatment decisions for severe MPP.
  • Findings contribute to a better understanding of the clinical spectrum and management of severe Mycoplasma pneumoniae pneumonia in pediatric populations.